Rare Disease Intelligence

Strategic coverage of orphan drug development, regulatory reform and competitive landscape dynamics.

---

The Rise of China’s Rare Disease Drugs: From Follower to Emerging Global Leader

February 27, 2026

China’s rare disease drug industry is transitioning from generics-based participation to innovation-driven global competitiveness, supported by regulatory reform, biotechnology advancement, cost efficiency, and industrial integration.

---

Why Humanity Continues to Invest in Orphan Drug Research — Despite Only 5% of Rare Diseases Being Treatable

February 27, 2026

Only 5% of rare diseases have approved treatments. Yet global investment in orphan drug research continues to grow. This article examines the scientific, ethical, and systemic drivers behind sustained rare disease innovation.

---